COENZYME Q AND REMACEMIDE IN HUNTINGTONS DISEASE

辅酶 Q 和瑞马酰胺治疗亨廷顿病

• 批准号: 6309916
• 负责人: FRANCIS O WALKER
• 金额: $ 3.88万
• 依托单位: WAKE FOREST UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-12-01 至 2001-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6309916
• 关键词: Huntington's disease; bioenergetics; clinical research; human subject; human therapy evaluation; mental disorder chemotherapy; neuroprotectants; ubiquinone

Animal models have suggested that glutamate neurotoxicity or metabolic impairment may cause neurodegeneration in HD. Remacemide, a drug with glutamate antagonist properties, has been safely tested in HD patients. Co-Enzyme Q10, a metabolic enhancer, has shown preliminary success in reversing metabolic markers of HD. This double-blind, This research study will evaluate the effects of Co-enzyme Q10 and Remacemide on the symptoms of Huntington's Disease (HD). The brain cell death that is the cause of HD is thought to be possibly caused by a) over-activity of the natural brain chemical glutamate, b) a lack of normal cell energy, or c) harmful brain substances called free radicals. Remacemide is an experimental drug that may be useful in treating HD by adjusting the activity of glutamate in the brain. Co-enzyme Q10 (CoQ) is a marketed product that may be useful in HD because it increases cell energy and decreases free radicals. This study will evaluate the potential benefits and safety of remacemide and CoQ, alone or in combination, on the features of HD.

动物模型表明，谷氨酸神经毒性或代谢障碍可能会导致HD神经退行性。 Memacemide是一种具有谷氨酸拮抗剂特性的药物，已在HD患者中进行了安全测试。 代谢增强剂Co-Conzyme Q10在逆转HD的代谢标记方面已显示出最初的成功。 这项双盲研究将评估共同酶Q10和纪机化酶对亨廷顿氏病（HD）症状的影响。脑细胞死亡是HD原因被认为可能是由a）天然脑化学谷氨酸的过度活动引起的，b）缺乏正常细胞能量，或c）称为自由基的有害脑物质。 莱克梅德是一种实验性药物，可以通过调整谷氨酸在大脑中的活性来治疗HD。 共酶Q10（COQ）是一种销售的产品，可能在HD中有用，因为它会增加细胞能量并减少自由基。这项研究将对HD的特征评估透镜和COQ的潜在益处和安全性。